Staphylococcal infection
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- An infection caused by Staphylococcus.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Staphylococcal infection
- Therapeutic area
- Infectious Disease
- staphylococcal infection
- staphylococcal infection
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0024313
- Parent condition
- MONDO:0005113
Related records
Broader conditions (6)
- Bacterial infectious disease
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
Narrower conditions (20)
- Bullous impetigo
- Chalazion
- Ecthyma
- Hordeolum
- Hordeolum externum
- Impetigo
- Impetigo herpetiformis
- Internal hordeolum
- Methicillin-resistant staphylococcus aureus infectious disease
- Methicillin-susceptible staphylococcus aureus infectious disease
- Staphylococcal necrotizing pneumonia
- Staphylococcal pneumonia
- Staphylococcal scalded skin syndrome
- Staphylococcal scarlet fever
- Staphylococcal toxemia
- Staphylococcal toxic-shock syndrome
- Staphylococcus aureus infection
- Staphylococcus aureus pneumonia
- Staphylococcus discitis
- Staphyloenterotoxemia
Trials (290)
- 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
- A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection
- A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
- A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
- A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
- A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
- A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
- A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA
- A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections
- A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection
- A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
- A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
- A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis
- A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
- A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
- A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults
- A Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
- A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely
- Adjunctive Clindamycin for Cellulitis: C4C Trial.
- Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
Approved drugs (2)
- Ertapenem sodium
- Retapamulin
Drugs in development (8)
- Cefilavancin Phase 2
- Ceftazidime Phase 3
- Ceftobiprole medocaril sodium Phase 3
- Exebacase Phase 1
- Omodenbamab Phase 1
- Telavancin Phase 3
- Vancomycin Phase 3
- Vancomycin hydrochloride Phase 3
Other linked drugs (4)
- Chlorhexidine gluconate
- Clindamycin
- Linezolid
- Rifampin